` APM (Aptorum Group Ltd) vs S&P 500 Comparison - Alpha Spread

APM
vs
S&P 500

Over the past 12 months, APM has underperformed S&P 500, delivering a return of -53% compared to the S&P 500's +13% growth.

Stocks Performance
APM vs S&P 500

Loading
APM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
APM vs S&P 500

Loading
APM
S&P 500
Difference
www.alphaspread.com

Performance By Year
APM vs S&P 500

Loading
APM
S&P 500
Add Stock

Competitors Performance
Aptorum Group Ltd vs Peers

S&P 500
APM
ABBV
AMGN
GILD
VRTX
Add Stock

Aptorum Group Ltd
Glance View

Market Cap
11.5m USD
Industry
Biotechnology

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

APM Intrinsic Value
Not Available
Back to Top